CStone Pharmaceuticals (CSPHF) Stock Price & Analysis
CStone Pharmaceuticals (CSPHF) — price $0.75 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.20B.
Educational signal · not a buy or sell recommendation · How to read this
CStone Pharmaceuticals · CSPHF
CStone Pharmaceuticals is a biopharmaceutical company focused on developing immuno-oncology and precision medicines for cancer treatment.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.75 | |
| Change on the day | 0.00% | |
| 52-week range | $0.5945 – $1.01 | |
| Market capitalisation | $1.20B | — |
| Shares traded on the day | 2.0K |
Price & events
Other perspectives
Council score for CStone Pharmaceuticals (CSPHF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is CStone Pharmaceuticals (CSPHF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CStone Pharmaceuticals (CSPHF) is the company analyzed here. It employs 93 people and is led by Jianxin Yang. In Q2 FY2026 it reported revenue of CN¥202M and net income of -CN¥249M. The market values it at $1.20B.
What do the latest results show for CStone Pharmaceuticals (CSPHF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥202M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥202M | -CN¥249M | -CN¥0.16 (diluted) |
| Q4 FY2025 | CN¥216M | -CN¥164M | -CN¥0.11 (diluted) |
| Q2 FY2025 | CN¥25M | -CN¥135M | -CN¥0.10 (diluted) |
| Q4 FY2024 | CN¥153M | -CN¥107M | -CN¥0.08 (diluted) |
What are the financial strengths and risks for CStone Pharmaceuticals (CSPHF)?
Short answer · as of
The distress and quality screens read Altman Z 6.61 · Piotroski F 4. Trailing ratios: ROE -43.5% · ROA -20.2% · current ratio 3.58 · earnings yield -6.2% · free-cash-flow yield -3.9%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CSPHF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CSPHF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about CStone Pharmaceuticals (CSPHF)?
- Kimia Therapeutics Advances Oncology Asset to Clinical Stage in Collaboration with CStone Pharmaceuticals
- CStone and Kimia Therapeutics Enter Clinical Development Collaboration to Advance a Novel Drug Candidate Targeting Repair Pathways Critical for Solid Tumor Survival
- CStone Pharmaceuticals (SEHK:2616) ESMO Update Puts Its Valuation Debate Back In Focus
- CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
Common Questions About CSPHF
These answers are editorial: 1 of these 8 answers is drawn from the CSPHF research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CSPHF a good stock to buy?
Stock Expert AI does not rate CSPHF buy, sell or hold. CStone Pharmaceuticals has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CSPHF stock price today?
The last price recorded for CStone Pharmaceuticals (CSPHF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does CStone Pharmaceuticals do?
CStone Pharmaceuticals is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines. Its product offerings include monoclonal antibodies and small molecule inhibitors aimed at treating various types of cancer, addressing significant unmet medical needs in both China and international markets.
What are the key factors to evaluate for CSPHF?
Evaluate CSPHF on fundamentals, analyst consensus, and risk factors. No dividend yield, consistent with many biotech firms focused on growth. Not financial advice.
How frequently does CSPHF data refresh on this page?
CSPHF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CSPHF's recent stock price performance?
CStone Pharmaceuticals (CSPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline addressing critical cancer treatment needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSPHF overvalued or undervalued right now?
CStone Pharmaceuticals (CSPHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CSPHF before investing?
Before investing in CStone Pharmaceuticals (CSPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com